MedTrace Logo

Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)

NCT00156962 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 850

Last updated 2008-07-21

No results posted yet for this study

Summary

The purpose of this study is to look at subject incidence of adverse events.

Conditions

Interventions

DRUG

Epoetin alfa DT

Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL

DRUG

Epoetin alfa RB

Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2007-03-31
Completion
2007-03-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00156962 on ClinicalTrials.gov